�CV Therapeutics,
Inc. (Nasdaq: CVTX) proclaimed that the company has enrolled the first
patient in a Phase 1 trial of CVT-3619, a novel oral compound for potential
discourse of cardiometabolic diseases. The U.S. Food and Drug
Administration latterly accepted the Company's investigational new drug
application for CVT-3619, a partial A1 adenosine sensory receptor agonist.
This Phase 1 trial volition assess the safety and pharmacokinetic profile
of CVT-3619 in healthy volunteers. The Phase 1 program volition provide early
data on the compound's potential personal effects on circulating levels of free
butterball acids, which are associated with senior high blood lipide levels, insulin
resistance and other cardiometabolic risk factors.
"Despite current therapies, millions of Americans continue to suffer
from both tenderness disease and diabetes. CVT-3619 is a first in class, potent,
orally useable new chemical entity that targets yet untreatable aspects
of dysfunctional metabolism in these patients," said Louis G. Lange, M.D.,
Ph.D., chairman and chief administrator officer of CV Therapeutics. "CVT-3619
was invented by CV Therapeutics and represents our fourth part clinical programme
to complement our deuce approved products."
CVT-3619 binds to the adenosine A1 receptor on fat cells, called
adipocytes, potentially leading to a reduction in the breakdown in fats,
also known as lipolysis, and a lowering of free fat person acids in preclinical
models. Preclinical studies also have shown that CVT-3619 improves insulin
sensitivity, reduces elevated triglycerides, and may lour very low density
lipoproteins and potentially raise heights density lipoproteins.
"CVT-3619 represents a first-in-class agent that appears to inhibit the
release of free fatso acids from fat cells and has the voltage to forgather a
awful unmet need by potentially treating both dyslipidemia and
diabetes. We look forwards to the clinical growth of this innovative
medication," said Ralph A. DeFronzo, M.D., professor of medicine and foreman
of the diabetes division at the University of Texas Health Science Center
in San Antonio, Texas.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical caller primarily focused on applying molecular
cardiology to the discovery, development and commercialization of novel,
small speck drugs for the intervention of cardiovascular diseases. CV
Therapeutics Ltd. is the company's European subsidiary based in the United
Kingdom.
CV Therapeutics' approved products in the United States include
Ranexa(R) (ranolazine extended-release tablets), indicated for the
treatment of chronic angina in patients who suffer not achieved an decent
response with other antianginal drugs, and Lexiscan(TM) (regadenoson)
injection for use as a pharmacological stress agent in radionuclide
myocardial perfusion imaging in patients unable to undergo adequate
exercise stress. Ranexa is too approved for use in the European Union as
add-on therapy for the symptomatic intervention of patients with stable angina
pectoris who are inadequately controlled or intolerant to first-line
antianginal therapies.
Except for the historical information contained herein, the matters set
forth in this press release, including statements as to inquiry and
growth and commercialisation of products, are innovative
statements inside the substance of the "safe harbour" provisions of the
Private Securities Litigation Reform Act of 1995. These advanced
statements ar subject to risks and uncertainties that may case actual
results to differ materially, including operating losses and fluctuations
in operating results; das Kapital requirements; regulative review and approval
of our products; special protocol assessment accord; the carry and
timing of clinical trials; commercialization of products; market acceptation
of products; product labeling; concentrated client base; reliance on
strategic partnerships and collaborations; uncertainties in dose
development; uncertainties regarding cerebral property and other risks
detailed from time to time in CV Therapeutics' SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements.
CV Therapeutics, Inc.
http://www.cvt.com
View do drugs information on Ranexa.
More information
